calsequestrin 1 CRISPR/Cas9 KO Plasmid (h): sc-403375
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- calsequestrin 1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the calsequestrin 1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: calsequestrin 1 Antibody (D-10): sc-137080
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
calsequestrin 1 CRISPR/Cas9 KO Plasmid (h) | sc-403375 | 20 µg | $397.00 |
Overview
CASQ1 encodes calsequestrin 1, a high-capacity Ca²⁺-binding protein localized to the lumen of the sarcoplasmic reticulum in skeletal muscle, where it buffers Ca²⁺ and helps shape excitation–contraction coupling. By interacting with ryanodine receptor complexes and junctional SR components, CASQ1 supports Ca²⁺ release and reuptake dynamics that govern contractility, fatigue resistance, and myofiber homeostasis. Perturbation of CASQ1-dependent Ca²⁺ handling is linked to altered intracellular Ca²⁺ signaling, oxidative stress responses, and remodeling of SR architecture. Genetic and functional studies have implicated CASQ1 in susceptibility to malignant hyperthermia–like phenotypes and other skeletal muscle disorders characterized by impaired Ca²⁺ storage and dysregulated Ca²⁺ release.
calsequestrin 1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CASQ1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CASQ1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CASQ1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish calsequestrin 1 protein expression.
This CRISPR knockout system enables efficient generation of CASQ1-deficient cell models for investigation of calsequestrin 1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CASQ1 exon(s) critical for calsequestrin 1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CASQ1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by calsequestrin 1 CRISPR/Cas9 KO Plasmid (h) and calsequestrin 1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CASQ1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by calsequestrin 1 HDR Plasmid (h) and calsequestrin 1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CASQ1 homology arms to support homology-directed repair at defined CASQ1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.